Trinity Biotech (TRIB) Stock Price, News & Analysis

Company Overview

Trinity Biotech plc is a biotechnology and medical diagnostics company headquartered in Bray, Ireland. The company develops, manufactures and markets diagnostic products used by clinical laboratories, healthcare professionals and patients.

Its product portfolio includes tests for infectious diseases, autoimmune disorders and diabetes. Trinity Biotech is particularly known for HIV diagnostic products, including rapid and laboratory-based testing solutions, as well as assays and instruments used in clinical testing. The company has also developed products for measuring glycated hemoglobin, an important indicator used in diabetes management.

Trinity Biotech serves customers through direct sales and distribution relationships in the United States and international markets, including Europe, Africa and Asia. Its products are used in hospitals, laboratories, physician offices, public-health programs and other healthcare settings.

Founded in 1992, Trinity Biotech has expanded its business through internal product development and acquisitions of diagnostic companies and technologies. The company is listed on the Nasdaq Capital Market under the symbol TRIB.

Key Stats

• Today's Range: $6.21 to $8.36
• 50-Day Range: $5.69 to $13.38
• 52-Week Range: $5.01 to $52.50
• Volume: 27,358 shs
• Average Volume: 12,763 shs
• Market Capitalization: $6.45 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Trinity Biotech Stock Analysis - MarketRank™

Trinity Biotech scored higher than 9% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Trinity Biotech has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Trinity Biotech has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Trinity Biotech is -0.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Trinity Biotech is -0.18, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

2.40% of the float of Trinity Biotech has been sold short.

Short Interest Ratio / Days to Cover

Trinity Biotech has a short interest ratio ("days to cover") of 2.13, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Trinity Biotech has recently increased by 123.35%, indicating that investor sentiment is decreasing significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: Weak

Dividend Yield

Trinity Biotech does not currently pay a dividend.

Dividend Growth

Trinity Biotech does not have a long track record of dividend growth.

News and Social Media

• Score: 2.9 / 5
• News Sentiment: 0.60

News Sentiment

Trinity Biotech has a news sentiment score of 0.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.73 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 3 news articles for Trinity Biotech this week, compared to 1 article on an average week.

MarketBeat Follows

1 people have added Trinity Biotech to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Trinity Biotech insiders have not sold or bought any company stock.

Percentage Held by Insiders

8.20% of the stock of Trinity Biotech is held by insiders.

Percentage Held by Institutions

78.97% of the stock of Trinity Biotech is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 6/16/2026
• Today: 10/15/2026
• Next Earnings (Estimated): 12/10/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: N/A
• Current Symbol: NASDAQ:TRIB
• CIK: 888721
• Web: www.trinitybiotech.com
• Phone: (531) 276-9800
• Fax: 353-1276-9888
• Employees: 287
• Year Founded: 1992

Profitability

• EPS (Trailing Twelve Months): ($44.26)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$37.38 million
• Net Margins: -70.06%
• Pretax Margin: -69.70%
• Return on Equity: N/A
• Return on Assets: -32.13%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.22
• Quick Ratio: 0.09

Sales & Book Value

• Annual Sales: $43.79 million
• Price / Sales: 0.15
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($601.80) per share
• Price / Book: -0.01

Miscellaneous

• Outstanding Shares: 813,000
• Free Float: 746,000
• Market Cap: $6.45 million
• Optionable: Optionable
• Beta: 0.73